Statistical Sampling: an Underestimated Element of Process Validation?
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In a recent FDA Warning Letter, the FDA criticized inadequate process validation for a semi-solid dosage form. What exactly did the FDA find inadequate?
The validation studies were criticized for not reflecting inter- and intra-batch variability. In particular, there was criticism that the sampling was random. The viscosity sampling scheme does not lead to statistical confidence in process performance.
In a second Process Performance Qualification (PPQ) study, the influence of a critical excipient on viscosity was to be shown. Again, the FDA criticized that no inter-batch variability was demonstrated. This is not surprising, since only one run was performed.
As measures, the FDA requires:
- a validation programme, starting with product development, the validation itself and the control/monitoring of the processes with regard to intra- and inter-batch variability
- an equipment and premises qualification programme
- a programme for Process Performance Qualification and Continued Process Verification measures.
You can find the entire Warning Letter on the FDA website.
Related GMP News
04.02.2026ECA Survey Results II: How is Statistical Process Control used in the Pharmaceutical Industry?
28.01.2026ECA Survey Results I: How is Statistical Process Control used in the Pharmaceutical Industry?
28.01.2026New FDA Term in the Field of Equipment
28.01.2026Process Validation covers the entire Manufacturing Process
29.10.2025Qualification does not replace Validation
15.10.2025Documented Evidence - a fundamental Principle at the FDA